RecruitingNot ApplicableNCT04838899

Stereotactic Ablative Radiation Therapy for Abiraterone-Resistant, Oligoprogressive Metastatic Prostate Cancer

Stereotactic Ablative Radiotherapy for Oligoprogressive Metastatic Castration-Resistant Prostate Cancer During Abiraterone Therapy

Sponsor

Sunnybrook Health Sciences Centre

Enrollment

30 participants

Start Date

Jul 16, 2016

Study Type

INTERVENTIONAL

Conditions

Oligoprogressive

Summary

There is increasing worldwide interest in exploring stereotactic ablative body radiotherapy (SABR) for treating metastases in men with prostate cancer, including for the treatment of oligoprogressive metastases. The latter applies to a situation whereby patients with widespread metastases undergoing systemic therapy present with a solitary or a few metastatic tumors that progress, while all other metastases are stable or responding. The usual practice would be to change systemic therapy at this point, but another approach is to locally ablate the "rogue" metastases and continue the same systemic therapy. SABR used in this scenario may delay the need to switch to another line of systemic therapy and improve progression-free survival while patients stay on the same systemic therapy.

Eligibility

Sex: MALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether adding targeted radiation (a precise treatment called SABR) to specific sites where prostate cancer is progressing — while continuing the hormone therapy drug abiraterone — can extend the time before the disease spreads further. **You may be eligible if:** - You have metastatic prostate cancer that is no longer responding to hormone treatment (castration-resistant) - You are currently being treated with abiraterone - Only a small number of cancer spots are progressing (5 or fewer) while others remain stable - All progressing spots can be safely treated with targeted radiation - You are in good overall health (ECOG 0–1) **You may NOT be eligible if:** - You have significant cancer pain requiring opioid pain medication - You urgently need chemotherapy - Your cancer is pressing on the spinal cord - You have had another cancer in the past 5 years (other than minor skin cancers) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.